A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)

  • Spencer, Andrew (Primary Chief Investigator (PCI))
  • Malherbe, Maturos (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date6/09/22 → 30/11/24

Keywords

  • Clinical trial
  • multiple myeloma
  • drug administration
  • isatuximab
  • pomalidomide
  • dexamethasone